Control of inflammatory heart disease by CD4+ T cells

Annals of the New York Academy of Sciences

Volumn 1285, Issue 1, 2013, Pages 80-96

  Barin, Jobert G ^a   Čiháková, Daniela ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disease; Cytokines; Myocarditis; Th17 cells

Indexed keywords

CARDIAC MYOSIN; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DQ8 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERTUSSIS TOXIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; ENCEPHALOMYOCARDITIS VIRUS; EOSINOPHIL; EOSINOPHILIA; GENETIC PREDISPOSITION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HELPER CELL; HUMAN; INFLAMMATORY DILATED CARDIOMYOPATHY; INFLAMMATORY DISEASE; IPEX SYNDROME; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; MYOCARDITIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERICARDITIS; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

EID: 84878178882     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12134     Document Type: Article

References (182)

1. Andreoletti, L. et al. 2009. Viral causes of human myocarditis. Arch. Cardiovasc. Dis. 102: 559-568.
2. Frustaci, A. et al. 2003. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107: 857-863.
3. Frustaci, A., M.A. Russo & C. Chimenti 2009. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur. Heart J.
4. Aretz, H.T. et al. 1987. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1: 3-14.
5. Basso, C. et al. 2012. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail. Rev.
6. Elliott, P. et al. 2008. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 29: 270-276.
7. Maron, B. J. et al. 2006. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807-1816.
8. Cooper, L.T. Jr. et al. 2008. Usefulness of immunosuppression for giant cell myocarditis. Am. J. Cardiol. 102: 1535-1539.
9. Magnani, J.W. & G.W. Dec 2006. Myocarditis: current trends in diagnosis and treatment. Circulation 113: 876-890.
10. Felker, G.M. et al. 2000. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342: 1077-1084.
11. Herskowitz, A. et al. 1993. Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am. J. Cardiol. 71: 982-986.
12. Magnani, J.W. et al. 2006. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am. Heart J. 151: 463-470.
13. Rose, N.R. 2012. Infection and autoimmunity: theme and variations. Curr. Opin. Rheumatol. 24: 380-382.
14. Neu, N. et al. 1987. Cardiac myosin induces myocarditis in genetically predisposed mice. J. Immunol. 139: 3630-3636.
15. Cihakova, D. et al. 2004. Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol. Med. 102: 175-193.
16. Smith, S.C. & P.M. Allen 1991. Myosin-induced acute myocarditis is a T cell-mediated disease. J. Immunol. 147: 2141-2147.
17. Smith, S.C. & P.M. Allen 1993. The role of T cells in myosin-induced autoimmune myocarditis. Clin. Immunol. Immunopathol. 68: 100-106.
18. Gangaplara, A. et al. 2012. Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-alpha-reactive CD4 T cells in A/J mice. Clin. Immunol. 144: 237-249.
19. Malkiel, S., S. Factor & B. Diamond 1999. Autoimmune myocarditis does not require B cells for antigen presentation. J. Immunol. 163: 5265-5268.
20. Mosmann, T.R. & R.L. Coffman 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145-173.
21. Shioi, T., A. Matsumori & S. Sasayama 1996. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 94: 2930-2937.
22. Schmidtke, M. et al. 2000. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis. J. Med. Virol. 61: 518-526.
23. Luppi, P. et al. 2001. Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy. J. Autoimmun. 16: 3-13.
24. Luppi, P. et al. 2003. Expansion of specific alphabeta+ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with Coxsackievirus B infection. Hum. Immunol. 64: 194-210.
25. Yamamoto, N. et al. 1998. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 97: 1017-1023.
26. Taneja, V. & C.S. David 2009. Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8.NODAbo transgenic mice. J. Autoimmun. 33: 260-269.
27. Taneja, V. et al. 2007. Spontaneous myocarditis mimicking human disease occurs in the presence of an appropriate MHC and non-MHC background in transgenic mice. J. Mol. Cell. Cardiol. 42: 1054-1064.
28. Reifenberg, K. et al. 2007. Interferon-{gamma} induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am. J. Pathol. 171: 463-472.
29. Torzewski, M. et al. 2012. Chronic inflammatory cardiomyopathy of interferon gamma-overexpressing transgenic mice is mediated by tumor necrosis factor-alpha. Am. J. Pathol. 180: 73-81.
30. Afanasyeva, M. et al. 2001. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 104: 3145-3151.
31. Eriksson, U. et al. 2001. Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma. J. Immunol. 167: 5464-5469.
32. Okura, Y. et al. 1998. Recombinant murine interleukin-12 facilitates induction of cardiac myosin-specific type 1 helper T cells in rats. Circ. Res. 82: 1035-1042.
33. + myeloid cells. J. Immunol. 163: 3503-3510.
34. Caspi, R.R. et al. 1994. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J. Immunol. 152: 890-899.
35. Eriksson, U. et al. 2001. Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation 103: 18-21.
36. Rangachari, M. et al. 2006. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J. Exp. Med. 203: 2009-2019.
37. Fairweather, D. et al. 2004. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am. J. Pathol. 165: 1883-1894.
38. + T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure. Proc. Natl. Acad. Sci. USA 102: 180-185.
39. Afanasyeva, M. et al. 2004. Novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-gamma-knockout mice. Circulation 110: 2910-2917.
40. Tarrant, T.K. et al. 1999. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J. Exp. Med. 189: 219-230.
41. Dalton, D. K. et al. 2000. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med. 192: 117-122.
42. Barin, J.G. et al. 2010. Mechanisms of IFNgamma regulation of autoimmune myocarditis. Exp. Mol. Pathol. 89: 83-91.
43. Dalton, D.K. et al. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259: 1739-1742.
44. Chu, C.Q., S. Wittmer & D. K. Dalton 2000. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 192: 123-128.
45. Matthys, P., K. Vermeire & A. Billiau 2001. Mac-1(+) myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-gamma in autoimmune disease models. Trends Immunol. 22: 367-371.
46. Barin, J.G. et al. 2003. Thyroid-specific expression of IFN-gamma limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes. J. Immunol. 170: 5523-5529.
47. Seko, Y. et al. 1997. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3. J. Pathol. 183: 105-108.
48. Han, R.O. et al. 1991. Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. Biochem. Biophys. Res. Commun. 181: 520-523.
49. Afanasyeva, M. et al. 2001. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol. 159: 193-203.
50. Cihakova, D. et al. 2008. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am. J. Pathol. 172: 1195-1208.
51. Li, J. et al. 2007. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur. J. Pharmacol. 554: 60-68.
52. Satoskar, A.R. et al. 2000. Interleukin-4-deficient BALB/c mice develop an enhanced Th1-like response but control cardiac inflammation following Borrelia burgdorferi infection. FEMS Microbiol. Lett. 183: 319-325.
53. Soares, M. B. et al. 2001. Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. Am. J. Pathol. 159: 703-709.
54. Takemoto, N. et al. 1998. Th2-specific DNase I-hypersensitive sites in the murine IL-13 and IL-4 intergenic region. Int. Immunol. 10: 1981-1985.
55. Loots, G.G. et al. 2000. Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288: 136-140.
56. Wills-Karp, M. 2004. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202: 175-190.
57. Gor, D. O., N. R. Rose & N.S. Greenspan 2003. TH1-TH2: a procrustean paradigm. Nat. Immunol. 4: 503-505.
58. Shevach, E.M. 2000. Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. 18: 423-449.
59. Hori, S., T. Nomura & S. Sakaguchi 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
60. + regulatory T cells. Nat. Immunol. 4: 330-336.
61. Josefowicz, S.Z., L.F. Lu & A. Y. Rudensky 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30: 531-564.
62. Noutsias, M. et al. 2011. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur. J. Heart Fail. 13: 611-618.
63. - regulatory T cells. J. Immunol. 176: 4748-4756.
64. Shi, Y. et al. 2010. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation 121: 2624-2634.
65. + T cells in the acute phase of Trypanosoma cruzi infection. Microbes Infect. 10: 825-833.
66. Fousteri, G. et al. 2011. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J. Autoimmun. 36: 210-220.
67. Kaya, Z. et al. 2002. Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J. Immunol. 168: 1552-1556.
68. Horwitz, M.S. et al. 2006. Transforming growth factor-beta inhibits coxsackievirus-mediated autoimmune myocarditis. Viral. Immunol. 19: 722-733.
69. Frisancho-Kiss, S. et al. 2009. Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav. Immun. 23: 649-657.
70. Sardella, G. et al. 2007. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. Thromb. Res. 120: 631-634.
71. lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterios. Thromb. Vasc. Biol. 30: 1832-1841.
72. Carvalheiro, T. et al. 2012. Phenotypic and functional alterations on inflammatory peripheral blood cells after acute myocardial infarction. J. Cardiovasc. Trans. Res. 5: 309-320.
73. Lv, H. et al. 2011. Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans. J. Clin. Invest. 121: 1561-1573.
74. Tivol, E.A. et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
75. Okazaki, T. et al. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9: 1477-1483.
76. Lucas, J.A. et al. 2008. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181: 2513-2521.
77. Wang, J. et al. 2010. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22: 443-452.
78. Okazaki, T. et al. 2011. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J. Exp. Med. 208: 395-407.
79. Wildin, R.S., S. Smyk-Pearson & A.H. Filipovich 2002. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39: 537-545.
80. Barzaghi, F., L. Passerini & R. Bacchetta 2012. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front. Immunol. 3: 211.
81. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132.
82. Park, H. et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
83. Veldhoen, M. et al. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
84. McGeachy, M.J. et al. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10: 314-324.
85. + T helper cells. Cell 126: 1121-1133.
86. Langrish, C.L. et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
87. Hu, Y. et al. 2011. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann. N.Y. Acad. Sci. 1217: 60-76.
88. Maddur, M.S. et al. 2012. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am. J. Pathol. 181: 8-18.
89. Sonderegger, I. et al. 2008. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205: 2281-2294.
90. Yamashita, T. et al. 2011. IL-6-mediated Th17 differentiation through RORgammat is essential for the initiation of experimental autoimmune myocarditis. Cardiovasc. Res. 91: 640-648.
91. Chen, P. et al. 2012. Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4(+) T cells. Clin. Exp. Immunol. 169: 79-88.
92. Baldeviano, G.C. et al. 2010. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ. Res. 106: 1646-1655.
93. Wilson, M.S. et al. 2010. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207: 535-552.
94. Yuan, J. et al. 2010. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J. Immunol. 185: 4004-4010.
95. da Matta Guedes, P.M. et al. 2010. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Neglect. Trop. Dis. 4: e604.
96. Yuan, J. et al. 2010. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J. Clin. Immunol. 30: 226-234.
97. Ding, L. et al. 2010. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ. J. 74: 523-530.
98. + T cell lineup. Nat. Immunol. 11: 36-40.
99. + Foxp3(-) effector T cells. Nat. Immunol. 9: 1347-1355.
100. Veldhoen, M. et al. 2008. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9: 1341-1346.
101. Elyaman, W. et al. 2009. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA 106: 12885-12890.
102. Cappuzzello, C. et al. 2011. Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J. Transl. Med. 9: 28.
103. Vistnes, M. et al. 2010. Circulating cytokine levels in mice with heart failure are etiology dependent. J. Appl. Physiol. 108: 1357-1364.
104. Aaltonen, K.J. et al. 2012. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7: e30275.
105. Afanasyeva, M. et al. 2004. Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am. J. Pathol. 164: 807-815.
106. Barin, J.G. et al. 2012. Macrophages participate in IL-17-mediated inflammation. Eur. J. Immunol. 42: 726-736.
107. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
108. Barin, J.G., N. R. Rose & D. Cihakova 2012. Macrophage diversity in cardiac inflammation: a review. Immunobiology 217: 468-475.
109. Mantovani, A., A. Sica & M. Locati 2005. Macrophage polarization comes of age. Immunity 23: 344-346.
110. Mosser, D.M. & J.P. Edwards 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
111. Nahrendorf, M. et al. 2007. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204: 3037-3047.
112. Ishiyama, S. et al. 1997. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 95: 489-496.
113. Shin, T. et al. 1998. An inhibitor of inducible nitric oxide synthase ameliorates experimental autoimmune myocarditis in Lewis rats. J. Neuroimmunol. 92: 133-138.
114. + T cell-mediated experimental autoimmune myocarditis. J. Immunol. 180: 2686-2695.
115. + macrophages in experimental autoimmune myocarditis. Cardiovasc. Res.
116. Khader, S.A., S.L. Gaffen & J.K. Kolls 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal. Immunol. 2: 403-411.
117. Kolls, J.K. & A. Linden 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476.
118. Liao, Y.H. et al. 2012. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J. Am. Coll. Cardiol. 59: 420-429.
119. Fairweather, D. et al. 2005. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. J. Immunol. 174: 261-269.
120. + T cell responses in the heart. Am. J. Pathol. 163: 2413-2420.
121. Kishimoto, C. et al. 2001. Enhanced production of macrophage inflammatory protein 2 (MIP-2) by in vitro and in vivo infections with encephalomyocarditis virus and modulation of myocarditis with an antibody against MIP-2. J. Virol. 75: 1294-1300.
122. Ritzman, A.M. et al. 2010. The chemokine receptor CXCR2 ligand KC (CXCL1) mediates neutrophil recruitment and is critical for development of experimental Lyme arthritis and carditis. Infect. Immun. 78: 4593-4600.
123. Arruda-Olson, A.M. et al. 2009. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ. Cardiovasc. Qual. Outcom. 2: 656-662.
124. Minatoguchi, S. et al. 2004. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109: 2572-2580.
125. Orlic, D. et al. 2001. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA 98: 10344-10349.
126. Kang, H.J. et al. 2012. Five-year results of intracoronary infusion of the mobilized peripheral blood stem cells by granulocyte colony-stimulating factor in patients with myocardial infarction. Eur. Heart J.
127. Honold, J. et al. 2012. G-CSF-stimulation and coronary reinfusion of mobilized circulating mononuclear proangiogenic cells in patients with chronic ischemic heart disease: five year results of the TOPCARE- G-CSF Trial. Cell Transplant.
128. Shimada, K. et al. 2010. Therapy with granulocyte colony-stimulating factor in the chronic stage, but not in the acute stage, improves experimental autoimmune myocarditis in rats via nitric oxide. J. Mol. Cell. Cardiol. 49: 469-481.
129. Parrillo, J.E. 1990. Heart disease and the eosinophil. N. Engl. J. Med. 323: 1560-1561.
130. Ginsberg, F. & J.E. Parrillo 2005. Eosinophilic myocarditis. Heart Fail. Clin. 1: 419-429.
131. Molina, H.A. & F. Kierszenbaum 1989. Eosinophil activation in acute and chronic chagasic myocardial lesions and deposition of toxic eosinophil granule proteins on heart myofibers. J. Parasitol. 75: 129-133.
132. Molina, H.A. & F. Kierszenbaum 1988. Immunohistochemical detection of deposits of eosinophil-derived neurotoxin and eosinophil peroxidase in the myocardium of patients with Chagas' disease. Immunology 64: 725-731.
133. Spry, C.J., M. Take & P.C. Tai 1985. Eosinophilic disorders affecting the myocardium and endocardium: a review. Heart Vess. Suppl. 1: 240-242.
134. Abston, E.D. et al. 2012. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ. Heart Fail. 5: 366-375.
135. Sanada, S. et al. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117: 1538-1549.
136. Seki, K. et al. 2009. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail. 2: 684-691.
137. Lee, Y.K. et al. 2009. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol.
138. Bettelli, E. et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
139. Massilamany, C. et al. 2011. Identification of novel mimicry epitopes for cardiac myosin heavy chain-alpha that induce autoimmune myocarditis in A/J mice. Cell Immunol. 271: 438-449.
140. Nindl, V. et al. 2012. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur. J. Immunol. 42: 2311-2321.
141. Noutsias, M., V.J. Patil & B. Maisch 2012. Cellular immune mechanisms in myocarditis. Herz
142. Zhao, Z. et al. 2011. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 217: 518-524.
143. Berghmans, N. et al. 2011. Interferon-gamma orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J. Interferon Cytokine Res. 31: 575-587.
144. Nakae, S. et al. 2007. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol. 81: 1258-1268.
145. Kelchtermans, H. et al. 2009. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthr. Res. Ther. 11: R122.
146. Lee, Y.K. et al. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
147. Hirota, K. et al. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12: 255-263.
148. + T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J. Immunol. 181: 4733-4741.
149. Huber, S.A. 2010. gammadelta T lymphocytes kill T regulatory cells through CD1d. Immunology 131: 202-209.
150. + FoxP3 (T regulatory) cell response in coxsackievirus B3-induced myocarditis. Immunology 127: 567-576.
151. Kaya, Z. et al. 2011. Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis. Cardiovasc. Res. 91: 116-123.
152. Matsumoto, K. et al. 2011. Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int. Heart J. 52: 382-387.
153. Tang, T.T. et al. 2012. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res. Cardiol. 107: 232.
154. Cooper, L.T., Jr., G.J. Berry & R. Shabetai 1997. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N. Engl. J. Med. 336: 1860-1866.
155. Yi, A. et al. 2009. The prevalence of Th17 cells in patients with dilated cardiomyopathy. Clinical and investigative medicine.Medecine Clinique Et Experimentale. 32: E144-E150.
156. Ong, K.L. et al. 2013. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann. Epidemiol. 23: 80-86.
157. Gisondi, P. et al. 2010. Usefulness of the framingham risk score in patients with chronic psoriasis. Am. J. Cardiol. 106: 1754-1757.
158. Mehta, N.N. et al. 2011. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am. J. Med. 124: 775 e771-776.
159. Tincani, A. et al. 2006. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology. 45 (Suppl. 4): iv8-13.
160. Abdel-Aty, H. et al. 2008. Myocardial tissue characterization in systemic lupus erythematosus: value of a comprehensive cardiovascular magnetic resonance approach. Lupus 17: 561-567.
161. Panchal, L. et al. 2006. Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 patients in India. J. Postgrad. Med. 52: 5-10; discussion 10.
162. Puig, L. 2012. Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermo-Sifiliograficas. 103: 853-862.
163. Langley, R.G. et al. 2012. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol.
164. Gordon, K.B. et al. 2012. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 132: 304-314.
165. Taleb, S. et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206: 2067-2077.
166. Armstrong, A.W. et al. 2011. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp. Dermatol. 20: 544-549.
167. Tzellos, T., A. Kyrgidis & C.C. Zouboulis 2012. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol.
168. Ryan, C. et al. 2011. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864-871.
169. Reich, K. et al. 2011. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol. 164: 862-872.
170. Greenbaum, L.A., R. Benndorf & W.E. Smoyer 2012. Childhood nephrotic syndrome-current and future therapies. Nat. Rev. Nephrol. 8: 445-458.
171. Garrett, J.K. et al. 2004. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol. 113: 115-119.
172. Plotz, S.G. et al. 2003. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med. 349: 2334-2339.
173. Rothenberg, M.E. et al. 2008. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 358: 1215-1228.
174. Moosig, F. et al. 2011. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann. Intern. Med. 155: 341-343.
175. Kim, S. et al. 2010. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J. Allergy Clin. Immunol. 125: 1336-1343.
176. Kim, Y.J. et al. 2004. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J. Allergy Clin. Immunol. 114: 1449-1455.
177. Klion, A.D. et al. 2004. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103: 2939-2941.
178. Wechsler, M.E. et al. 2012. Novel targeted therapies for eosinophilic disorders. J. Allergy Clin. Immunol. 130: 563-571.
179. Pummerer, C.L. et al. 1996. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J. Clin. Invest. 97: 2057-2062.
180. Donermeyer, D.L. et al. 1995. Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J. Exp. Med. 182: 1291-1300.
181. Kaya, Z. et al. 2008. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 118: 2063-2072.
182. Jane-wit, D. et al. 2002. A novel class II-binding motif selects peptides that mediate organ-specific autoimmune disease in SWXJ, SJL/J, and SWR/J mice. J. Immunol. 169: 6507-6514.